


I'm not robot  reCAPTCHA

Open

schizophrenia and in cellular and animal models of insulin receptor dysfunction. *Glutamatergic and schizophrenia: beyond the dopamine hypothesis*. Arch Gen Psychiatry 1988; 45: 789–796.CAS Article Google Scholar 17Geddes J, Freemantle N, Harrison P, Bebbington P . Cyclin-dependent kinase-5 is involved in neuregulin-dependent activation of phosphatidylinositol 3-kinase and Akt activity mediating neuronal survival. *Psychopharmacology (Berl)* 2004; 174: 151–162.CAS Article Google Scholar 105Kozlovsky N, Belmaker RH, Agam G . Do insulin-like growth factors underlie associations of birth complications, fetal and pre-adult growth with schizophrenia? *Biol Psychiatry* 2004; 56: 698–700.CAS Article PubMed Google Scholar 79Xu MQ, Xing QH, Zheng YL, Li S, Gao JJ, He G et al. *Mol Pharmacol* 2004; 66: 97–105.CAS PubMed PubMed Central Article Google Scholar Page 2 Clinical and biochemical measures Comparisons between SGAs Effectiveness Clz>Olz>Risp=Quet>Zip=Ari Degree of metabolic disturbances Clz>Olz>Risp=Quet>Zip=Ari Magnitude of effects on GSK Clz=Olz>Risp=Quet>Zip Abbreviations: Ari, aripiprazole; Clz, clozapine; GSK, glycogen synthase kinase; Olz, olanzapine; Quet, quetiapine; Risp, risperidone; SGAs, second-generation antipsychotic drugs; Zip, ziprasidone. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. *FEBS Lett* 2004; 560: 115–119.CAS PubMed PubMed Central Article Google Scholar 87Basta-Kaim A, Budziszewska B, Jaworska-Feil L, Tetich M, Kubera M, Leskiewicz M et al. *Brain Res* 2004; 1011: 58–68.CAS PubMed PubMed Central Article Google Scholar 89Lu XH, Dwyer DS . The role of DTNBP1, NRG1, and AKT1 in the genetics of schizophrenia in Finland. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CULASS 1). Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. *Int J Neuropsychopharmacol* 2003; 6: 117–120.CAS PubMed Article Google Scholar 107Beasley C, Cotter D, Everall I . *Neuroscience* 2003; 118: 501–512.CAS PubMed Article Google Scholar 72Engl J, Laimer M, Niederwanger A, Kranebitter M, Starzinger M, Pedrini MT et al. Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia. *Cell Signal* 2006; 18: 1876–1886.CAS PubMed Article Google Scholar 93Scassellati C, Bonvicini C, Perez J, Bocchio-Chiavetto L, Tura GB, Rossi G et al. The role of atypical antipsychotics in glucose/insulin dysregulation and the evolving role of the psychiatrist in a new era of drug treatment options. Schizophrenia as a GSK-3 dysregulation disorder. Haloperidol effect on intracellular signals system coupled to alpha1-adrenergic receptor in rat cerebral frontal cortex. Insulin signal transduction in human skeletal muscle: identifying the defects in type II diabetes. Meltzer, The Mechanism of Action of Novel Antipsychotic Drugs, *Schizophrenia Bulletin*, Volume 17, Issue 2, 1991, Pages 263–287. 1Lewis DA, Lieberman JA . GSK-3 and the neurodevelopmental hypothesis of schizophrenia. *J Cell Sci* 2003; 116: 1175–1186.CAS PubMed PubMed Central Article Google Scholar 54Beaulieu JM, Gainetdinov RR, Caron MG . Association study between genetic variants at the PIF5K2A gene locus and schizophrenia and bipolar affective disorder. *Schizophr Res* 1996; 22: 159–164.CAS PubMed Article Google Scholar 68Hahn CG, Umaphathy, Wang HY, Koneru R, Levinson DF, Friedman E . *Pharmacol Ther* 2006; 110: 117–134.CAS Article PubMed Google Scholar 44Bjornholm M, Zierath JR . *Neurosci Lett* 2005; 379: 32–36.CAS Article PubMed Google Scholar 62Saito T, Aghalar MR, Lachman HM . *Int J Neuropsychopharmacol* 2006; 9: 337–342.CAS Article PubMed Google Scholar 114Li X, Rosborough KM, Friedman AB, Zhu W, Roth KA . *Neuropsychopharmacology* 2007 [e-pub ahead of print].58Coyle JT . The metabolic syndrome: is this diagnosis necessary? *Hum Mol Genet* 2006; 15: 3024–3033.CAS PubMed PubMed Central Article Google Scholar 86Kang UG, Seo MS, Roh MS, Kim Y, Yoon SC, Kim YS . *Biol Psychiatry* 2005; 57: 533–542.CAS PubMed PubMed Central Article Google Scholar 112Alimohamad H, Sutton L, Mouyal J, Rajakumar N, Rushlow WJ . *J Clin Psychiatry* 2004; 65 (Suppl 18): 36–46.CAS PubMed Google Scholar 21Basu A, Meltzer HY . The role of the phosphatidylinositide 3-kinase-protein kinase B pathway in schizophrenia. *Am J Psychiatry* 2002; 159: 255–262.PubMed PubMed Central Article Google Scholar 15Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H et al. *Schizophr Res* 2004; 71: 377–382.Article Google Scholar 110Nadri C, Kozlovsky N, Agam G, Bersudsky Y . *Neuropsychobiology* 2004; 50: 16–20.CAS PubMed Article Google Scholar 94Meng J, Shi Y, Zhao X, Zhou J, Zheng Y, Tang R et al. Lithium and valproic acid treatments reduce PKC activation and receptor-G protein coupling in platelets of bipolar manic patients. *J Clin Psychiatry* 2002; 63 (Suppl 4): 12–19.CAS PubMed PubMed Central Google Scholar 20Newcomer JW . *Arch Gen Psychiatry* 2006; 63: 1079–1087.CAS PubMed PubMed Central Article Google Scholar 11Lieberman JA . *Schizophr Res* 2005; 76: 361–362.PubMed Article Google Scholar 63Jamra RA, Klein K, Villela AW, Becker T, Schulze TG, Schmael C et al. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. *Schizophr Res* 2001; 52: 101–105.CAS PubMed PubMed Central Article Google Scholar 100Kozlovsky N, Shanon-Weickert C, Tomaskovic-Crook E, Kleinman JE, Belmaker RH, Agam G . *Biol Psychiatry* 2007; 63: 449–457.PubMed PubMed Central Article CAS Google Scholar 84Amar S, Shaltiel G, Mann L, Shamir A, Dean B, Scarr E et al. *N Engl J Med* 2005; 353: 1209–1223.CAS Article PubMed Google Scholar 13Tandon R, Fleischacker WW . No association of GSK3beta gene (GSK3B) with Japanese schizophrenia. Mechanistic connections between glucose/lipid disturbances and weight gain induced by antipsychotic drugs. Functional selectivity and classical concepts of quantitative pharmacology. *Int J Neuropsychopharmacol* 2007; 11: 197–205.PubMed Google Scholar 85Hashimoto R, Numakawa T, Ohnishi T, Kumamaru E, Yagasaki Y, Ishimoto T et al. *Brain Res Dev Brain Res* 2003; 141: 33–37.CAS Article Google Scholar 104Harrison PJ . *J Biol Chem* 2003; 278: 35702–35709.CAS Article Google Scholar 48Lai WS, Xu B, Westphal KG, Paterlini M, Olivier B, Pavlidis P et al.